Decellularised Extracellular Carpets for the Innovative Production of Human Engineered Replicates

Información del proyecto

DECIPHER

Identificador del acuerdo de subvención: 101138593

DOI

10.3030/101138593

Proyecto cerrado

Fecha de la firma de la CE 28 Agosto 2023

Fecha de inicio 1 Enero 2024

Fecha de finalización 31 Diciembre 2025

Financiado con arreglo a

• European Research Council (ERC)

Coste total

Sin datos

Aportación de la UE

€ 150 000,00

Coordinado por

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Ireland

Periodic Reporting for period 1 - DECIPHER (Decellularised Extracellular Carpets for the Innovative Production of Human Engineered Replicates)

Período documentado: 2024-01-01 hasta 2025-12-31

Resumen del contexto y de los objetivos generales del proyecto

Cell-derived matrices are multi-functional biomaterials with very high therapeutic capacity. Despite the very promising data that have been obtained to-date in both preclinical and clinical settings, there is very slow commercial and clinical uptake. It has been argued that the very high cell numbers and the prolonged ex vivo culture periods required to develop them limit their applicability, as the manufacturing costs become too high for the healthcare providers to be able to afford them. As a result, functional therapies do not become available to patients. Prof Zevgolis has pioneered the macromolecular crowding technology in eukaryotic cell culture. Macromolecular crowding, through volume exclusion, enhances and accelerates extracellular matrix deposition. DECIPHER aimed to assess the potential of macromolecular crowding in the development of cell-derived matrices. As part of the technology development work-packages, we developed using macromolecular crowding cell-derived matrices using only a fraction of cells and time that traditional approaches require. Further, the enhanced deposited extracellular matrix acts as a depo of trophic and therapeutic factors that promote physiological healing. The commercial development work-packages confirmed the transformative potential of macromolecular crowding in the development of cell-derived matrices for a diverse range of sectors and markets. DECIPHER will contribute to the commercialisation of cell-derived matrices, increasing the international competitiveness of European-based biotech industries and creating new employment, markets and revenue.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Work-package 1 and work-package 2 (technology development work-packages): Cell-derived matrices with enhanced deposited extracellular matrix were developed using only a fraction of cells and time that traditional approaches require. The enhanced deposited matrix is associated with enhanced functionality. Further, the materials had within the acceptable limits remaining DNA content, making them safe for use in regenerative medicine sector, as well as the cell culture technologies sector, cellular agriculture sector and drug discovery sector.

Work-package 3, work package 4 and work-package 5 (commercial development work-packages): These commercial work-packages were conducted by an independent entity, experienced in market analysis; customer discovery and validation analysis; and exploitation opportunity and route to market analysis. Their comprehensive report clearly recognises the transformative potential of the DECIPHER project in a range of sectors and markets.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Data obtained from the technological work-packages and information obtained from the commercial work-packages very clear identify the commercial opportunity of the DECIPHER project. The team will now work for the development of a competitive European Innovation Council (EIC) Transition proposal. it is anticipated that a company will be formed in the coming months. Scientific, clinical and commercial leads are already in place.